Billy Wynne, J.D., is the Managing Partner of TRP Health Policy. A division of the Washington government relations firm Thorn Run Partners, TRP Health Policy combines industry-leading, actionable analysis and insight with sophisticated, informed advocacy to help healthcare organizations solve challenges and capitalize on opportunities in the Federal policy space.
TRP Health Policy is also home to Policy Hub, an online portal and daily digest delivering in-depth intelligence on every important regulatory and legislative development impacting healthcare.
Previously, Billy served as Health Policy Counsel to the U.S. Senate Finance Committee. He received his B.A. from Dartmouth College and his law degree from the University of Virginia.
Recent Posts by Billy Wynne
Legislative efforts have a lifespan but our health care system does not. So whether we are still rejoicing or recriminating, let’s take a look at some timeless principles we can apply to the ongoing effort to improve health care in the United States.
While the presidential candidates and others consider broad-based health care policies, the passage of which in the near term is dubious, there is a wide array of issues we can bank on Congress taking up, likely in one, consolidated legislative package.
The central theme of the MACRA Final Rule is its softening of key parameters in an effort to allay provider concerns, rally participation, and avoid adverse consequences out of the gate. The complexity and Icarian vision of MACRA abides, but CMS is all but ushering docs in with their bare hands.
The mother ship has landed. On Wednesday, April 27, CMS released the highly-anticipated proposed rule that would establish key parameters for the new Quality Payment Program. This post briefly outlines the key elements of the proposed rule.
This post will attempt to hone in on what an alternative payment model under MACRA really is, discuss the provider incentives under this path, and clarify what we know so far about efforts underway to create and implement them.
MACRA replaced the Sustainable Growth Rate with annual 0.5 percent payment increases for each of the next five years. Under one track, MACRA streamlines certain Medicare quality initiatives that affect reimbursement under a unified system known as the Merit-Based Incentive Payment System (MIPS).
The FDA's approval this year of the first biosimilar has prompted a flurry of regulatory activity. Key concerns raised by recent FDA guidance remain, as well as other widely anticipated but yet-to-be released regulatory activity, such as the pivotal interchangeability standard.
In a previous blog, I described “the coming storm” I anticipated would develop around the 340B drug discount program. With the October 27 comment window steadily approaching, let’s take a look at what the rule says and what it could mean for interested stakeholders.